Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Pyruvic acid
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Uses== Pyruvate is sold as a [[Anti-obesity medication|weight-loss supplement]], though credible science has yet to back this claim. A [[Clinical research|systematic review]] of six [[Clinical trial|trials]] found a statistically significant difference in body weight with pyruvate compared to [[placebo]]. However, all of the trials had methodological weaknesses and the magnitude of the effect was small. The review also identified [[Adverse effect|adverse events]] associated with pyruvate such as diarrhea, bloating, gas, and increase in [[low-density lipoprotein]] (LDL) cholesterol. The authors concluded that there was insufficient evidence to support the use of pyruvate for weight loss.<ref>{{cite journal|last1=Onakpoya|first1= I.|last2= Hunt|first2= K.|last3=Wider|first3= B.|last4= Ernst |first4=E.|title=Pyruvate supplementation for weight loss: a systematic review and meta-analysis of randomized clinical trials|doi=10.1080/10408398.2011.565890|journal=Crit. Rev. Food Sci. Nutr.|date=2014|volume=54|issue=1|pages=17–23|pmid=24188231|s2cid= 20241217}}</ref> There is also ''[[in vitro]]'' as well as ''[[in vivo]]'' evidence in hearts that pyruvate improves metabolism by [[NADH]] production stimulation and increases cardiac function.<ref name="Functional response of the isolated, perfused normoxic heart to pyruvate dehydrogenase activation by dichloroacetate and pyruvate.">{{cite journal |pmid=26142699 |title=Functional response of the isolated, perfused normoxic heart to pyruvate dehydrogenase activation by dichloroacetate and pyruvate. |last1=Jaimes |first1=R. III |doi=10.1007/s00424-015-1717-1 |date=Jul 2015 |journal=Pflügers Arch. |volume=468 |issue=1 |pmc=4701640 |pages=131–42}}</ref><ref>{{Cite journal|last1=Hermann|first1=H. P.|last2=Pieske|first2=B.|last3=Schwarzmüller|first3=E.|last4=Keul|first4=J.|last5=Just|first5=H.|last6=Hasenfuss|first6=G.|date=1999-04-17|title=Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study|journal=Lancet |volume=353|issue=9161|pages=1321–1323|issn=0140-6736|pmid=10218531|doi=10.1016/s0140-6736(98)06423-x|s2cid=25126646}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)